AQST insider granted 82,500 performance stock units
BRAENDER LORI J reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
BRAENDER LORI J reported acquisition or exercise transactions in this Form 4 filing.
Aquestive Therapeutics, Inc. Corporate Secretary Lori J. Braender received a grant of 82,500 Performance Stock Units on March 7, 2025. Each unit represents a contingent right to one share of common stock and measures performance from March 7, 2025 through March 7, 2028.
If earned under the performance formula, the units vest 100% on March 7, 2028, with the award expiring on that date. The filing notes it was submitted late due to an inadvertent administrative oversight.
Insider Trade Summary
Grant/Award: 82,500 shares
Grant/Award
1 txn
Insider
BRAENDER LORI J
Role
Corporate Secretary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Performance Stock Units | 82,500 | $0.00 | $0.00 |
Holdings After Transaction:
Performance Stock Units — 82,500 contracts (Direct)
Footnotes (2)
- F1. This Form 4 was filed late due to an inadvertent administrative oversight.
- F2. Each PSU represents a contingent right to receive one share of the Company's common stock. The PSUs measure performance from March 7, 2025 (Grant Date) through March 7, 2028 and, if earned, vest 100% on March 7, 2028. "Performance Price" means (i) the 30-day average Nasdaq closing price ending on the last day of the period from the Grant Date through the day before the second anniversary (First Pricing Period) and (ii) the highest 30-day average Nasdaq closing price during the period from the second through the third anniversary (Second Pricing Period).
Key Figures
Performance Stock Units granted: 82,500 units
Shares underlying PSUs: 82,500 shares
Exercise/Conversion price: $0.00 per unit
+3 more
6 metrics
Performance Stock Units granted
82,500 units
Grant to Corporate Secretary on March 7, 2025
Shares underlying PSUs
82,500 shares
Each PSU equals one share of common stock
Exercise/Conversion price
$0.00 per unit
Performance Stock Units granted at no cash exercise price
Expiration/Vesting date
March 7, 2028
PSUs measure performance through and vest 100% on this date
Performance period start
March 7, 2025
Grant Date and beginning of PSU performance measurement
Derivative transactions reported
1 transaction
Single derivative-type grant acquisition in this Form 4
Key Terms
Performance Stock Units, Performance Price, Grant Date
3 terms
Performance Stock Units financial
"security_title: "Performance Stock Units""
Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.
Performance Price financial
""Performance Price" means (i) the 30-day average Nasdaq closing price"
Grant Date financial
"measure performance from March 7, 2025 (Grant Date) through March 7, 2028"
The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Aquestive Therapeutics (AQST) report for Lori J. Braender?
Aquestive Therapeutics reported that Corporate Secretary Lori J. Braender received 82,500 Performance Stock Units on March 7, 2025. These units are a stock-based compensation award tied to company performance over a three-year period ending March 7, 2028.
How many Performance Stock Units were granted in this AQST Form 4 filing?
The filing shows a grant of 82,500 Performance Stock Units to Lori J. Braender. Each unit represents a contingent right to receive one share of Aquestive Therapeutics common stock, subject to meeting specified performance conditions through March 7, 2028.
When do the granted Performance Stock Units for AQST potentially vest and expire?
If earned, the Performance Stock Units vest 100% on March 7, 2028 and expire that same day. The performance period runs from the March 7, 2025 grant date through March 7, 2028, aligning measurement and vesting with the award’s three-year term.
How is the “Performance Price” defined for the AQST Performance Stock Units?
Performance Price is based on 30-day average Nasdaq closing prices over two periods. The first measures the average ending the day before the second anniversary; the second uses the highest 30-day average between the second and third anniversaries from the March 7, 2025 grant date.
Did Aquestive Therapeutics disclose any issue with the timing of this Form 4 filing?
Yes. A footnote states that the Form 4 was filed late due to an inadvertent administrative oversight. This indicates the underlying grant occurred earlier, but the reporting of the transaction to the SEC was delayed unintentionally, according to the company’s explanation.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates